C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2026)

C4 Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $27.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 33.25% year-over-year to $27.2 million; the TTM figure through Mar 2026 stood at $27.2 million (down 33.25% YoY), while the FY2025 annual figure was $33.0 million, down 26.88% from the prior year.
• Total Current Liabilities was $27.2 million for Q1 2026 at C4 Therapeutics, down from $33.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $55.0 million in Q1 2024 to a low of $27.2 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $42.5 million across 5 years, with a median of $44.5 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities surged 43.02% in 2024, then slumped 33.25% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $44.5 million in 2022, then fell by 4.0% to $42.8 million in 2023, then increased by 5.64% to $45.2 million in 2024, then retreated by 26.88% to $33.0 million in 2025, then dropped by 17.51% to $27.2 million in 2026.
• The last three Total Current Liabilities figures came in at $27.2 million (Q1 2026), $33.0 million (Q4 2025), and $35.9 million (Q3 2025), per Business Quant data.